Physician profile
Magda E Melchert
NPI 1376596346
$5,672.25
in general payments reported to CMS, 2019-2025
52 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $225 · 2021: $162 · 2022: $583 · 2023: $1,399 · 2024: $1,058 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,696.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $719.92 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $504.82 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $422.73 | 2019-2025 | |
| Glaxosmithkline, LLC. | $285.75 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Lilly USA, LLC | $268.26 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $259.66 | 2019-2025 | Tecentriq, Venclexta, Alecensa |
| Merck Sharp & Dohme LLC | $234.09 | 2019-2024 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $231.89 | 2019-2025 | |
| Celgene Corporation | $222.76 | 2019-2025 | Reblozyl, Pomalyst |
| Gilead Sciences, INC. | $184.23 | 2019-2025 | Trodelvy |
| Daiichi Sankyo INC. | $175.76 | 2022-2025 | Enhertu, Datroway |
| Abbvie INC. | $133.61 | 2022-2025 | |
| Array Biopharma INC | $124.01 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Amgen INC. | $113.51 | 2019-2023 | Kyprolis |
| Sirtex Medical INC | $104.33 | 2019-2022 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $102.81 | 2022-2023 | Padcev, Adcetris, Tukysa |
| Eisai INC. | $99.26 | 2019-2025 | |
| Boston Scientific Corporation | $86.79 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Beigene USA, INC. | $85.73 | 2022-2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $79.85 | 2020-2023 | Calquence |
| Myriad Genetic Laboratories, INC. | $78.17 | 2023-2024 | Myrisk |
| Regeneron Healthcare Solutions, INC. | $72.34 | 2021-2023 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $67.05 | 2019-2024 | Fruzaqla, Alunbrig |
| Inari Medical, INC. | $57.86 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Springworks Therapeutics, INC. | $55.03 | 2024 | Ogsiveo |
| Exelixis INC. | $54.32 | 2021-2023 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $52.74 | 2020-2023 | |
| Sobi, INC | $52.35 | 2022-2024 | |
| Genzyme Corporation | $51.08 | 2023-2025 | |
| Astellas Pharma US INC | $48.18 | 2019-2025 | Padcev |
| Aadi Bioscience, INC. | $47.37 | 2024 | Fyarro |
| Pharmaessentia USA Corporation | $45.94 | 2024 | Besremi |
| Tersera Therapeutics LLC | $45.60 | 2019-2025 | Zoladex |
| Taiho Oncology, INC. | $43.77 | 2023-2025 | |
| Mirati Therapeutics, INC. | $41.82 | 2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $40.37 | 2019 | |
| Ge Healthcare | $36.37 | 2022 | |
| Csl Behring | $36.29 | 2022-2023 | Afstyla, Idelvion |
| Incyte Corporation | $33.00 | 2020-2023 | Monjuvi |
| Kite Pharma, INC. | $30.24 | 2025 | Yescarta |
| Immunogen, INC. | $28.77 | 2023 | Elahere |
| Adaptive Biotechnologies Corporation | $24.20 | 2023 | Clonoseq |
| Jazz Pharmaceuticals INC. | $22.25 | 2024 | |
| Janssen Pharmaceuticals, INC | $21.37 | 2019-2020 | |
| Servier Pharmaceuticals LLC | $20.86 | 2024 | |
| Heron Therapeutics, INC. | $20.29 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $20.10 | 2019 | |
| Aveo Pharmaceuticals, INC. | $19.09 | 2023 | Fotivda |
| Tesaro, INC. | $18.81 | 2019 | |
| G1 Therapeutics, INC. | $17.70 | 2023 | Cosela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.21 | 2019 | |
| Agios Pharmaceuticals, INC. | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magda Melchert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.